Evidence map›Paper›PMID 41975102›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2026

GlyT1 (SLC6A9) inhibition in neurological and psychiatric disorders.

Daniel Pereira Cavalcante, Gustavo Almeida Carvalho, Antônio Ítalo Santos Nunes, Amanda Rodrigues Quintanilha, Lucas Rodrigues Couto Nascimento, Leonardo Caixeta, Henning Ulrich, Renato Santiago Gomez, Mauro Cunha Xavier Pinto

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniel Pereira CavalcanteDepartment of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO, Brazil.
Gustavo Almeida CarvalhoDepartment of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO, Brazil.
Antônio Ítalo Santos NunesDepartment of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO, Brazil.
Amanda Rodrigues QuintanilhaDepartment of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO, Brazil.
Lucas Rodrigues Couto NascimentoDepartment of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO, Brazil.
Leonardo CaixetaSchool of Medicine, Federal University of Goiás, Goiânia, GO, Brazil.
Henning UlrichInstitute of Chemistry, University of São Paulo, São Paulo, SP, Brazil.
Renato Santiago GomezSchool of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Mauro Cunha Xavier PintoDepartment of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO, Brazil. pintomcx@ufg.br.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 406765/2021-9Conselho Nacional de Desenvolvimento Científico e Tecnológico 407075/2018-6Fundação de Amparo à Pesquisa do Estado de Goiás AUX2024361000034Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-04596-25
6 · The paper itself

Abstract

Glycine is a fundamental neuroactive amino acid that serves dual roles in the central nervous system: acting as a primary inhibitory neurotransmitter via strychnine-sensitive glycine receptors and as an essential co-agonist at the N-methyl-D-aspartate (NMDA) receptor. This dual functionality is important for maintaining the excitation-inhibition balance, synaptic plasticity, and network stability. The spatial and temporal availability of glycine is strictly regulated by two high-affinity, Na

Indexed as

GlycineGlycine Plasma Membrane Transport ProteinsMental DisordersNervous System DiseasesAnimalsHumansGlycineGlycine Plasma Membrane Transport ProteinsSLC6A9 protein, humanAlzheimer’s diseaseExcitotoxicityGlycine transporter type 1Parkinson’s diseaseSchizophreniaSLC6A9Stroke

Identifiers

PMID41975102
PMCPMC13357455

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.